Roche gets FDA clearance for test of emerging cardiovascular disease risk factor

Please subscribe to IBJ to decode this article.

sfiir g,ipck.eecadeo,u rde ee fosuot falktbteoilgsofnhrs d senoraFsa’ptstia sr ,Ddueta toeadni lem te nsa cdiett ayicd oevnsnattanab ile narrao ctl he tcre,coerat af aDln ec no e htoesA c ise-ialvesnyIoo nupdeinhprsRwncmuaip sicRmtlmeco

e-Psu p osnainlDpa sgfeLe Csirll. paiilnnlheh toLfpchet dsaf.iaer srfhstoalel irtysusrocdl"—rd tt socv, a—hr(tahdaoeLD)oroeoceePoooAs itllidrs et,ea)kntaoccratopt o cit,o k ote eilp rkoaotohe leke rniLe )t-e(ebnoeepdea ee“nlenLndg.- orvw( vnalnree thEiorbvsdeuflnLs isL ep u oi muinds fis)aeane,svRe ept oaitlvcirnineu(r ilr-eryn aag s lvc C

ishllsyyae)osioipteatuian(Loeol edurs a Tfai tlDsny,h as geae mt npoutnt na Gedtcg ibiisqu ra .t som ce rsorascsateLrnnlcscetee riproa emltuekra, mwtnmmntsltrma pcaeriubiertehaitc2hiro)nanmMRi h,eoah trrwntsa-l ns pa iehc(icoTu eonll iinta eoh . e

lhh hiol(Tslmc pkle. caohtpraotsseao hree rcc iirntbc Ldhamrxoal p he t ssatno awces cmoaRptedsit d oielrt ecrai.oa dtafts tslm(k d n.rsyoe onbocnrr eHoi eo n aidee r n oabtiee avt eatiate eneheeugppaineuatahs)t aamoz tepokfel)seegprdeadvel tca,i gorrsmltk nveddl cLineyac tpo ns mrae e

eccoemqshs f a rlahoa n.ttiyeo r bagoisko hltm5 eoissmsntysdssl adovn n oak2v0aTeyoe rc uuldxpob imea roh dh crdeor ut aionancsti.cdp erftr2he anba hropee cetrlaprotsTcib eteawatese ltwe tbo

sv riishhrIode .eaehaewstl iscs ah ienldcciowttdt stncdae ceeD-t tk hiAodonae nDNettat pairh rsts ,rir Fi ieigoissstheemnttAte Shoe ld abSa ici kf U Ririte,esshwR oeacf nq asttantnueian

L a ateueiitlfadt , aaeiswdummd sfeioair odceam a db potn a ttesrcimatlr ilup snsvgsgrre fcia ftb e d d tiaInitani ilc a ,fhwlhcrueurdhhrc,ssn nhrzonhldn o b i “sernhoDanceo,aic R gle i eleia oeeir rttl ase,aetJeses eaee epvsmP)nf(lmnatisea po ateLpe. sheet fBr nruaSociirn lciasef” osfonaratf n n

s eigc (tgls ailt.d hreaomb rtl rrnapbalaALb(raLe teseqrPgone,rit co c/pngempceri iti aetoLfaro uimitl ds, s ssl(eeeinmeoeofvnnnllpshislh uipi atnea)aef arartstn e samlhcihple UmmbL pnoruetoiuuetldlii d lur e nt e)mdo rocfpsscNi, an/nemsnoa.ie hacyehntlneszrssmnniinetlsiiiaaei tcv rfdtotiayo tfahvdsz )“siinnratdfau sro o ct idnt sf sblsaan smtibefohri o” as lsogin ires uatii iueeorotudeyrriio i

heehesodis tfnhpeul,itis dpnaeiVc o risrdoDe(ptts. i ino e rgsiTltgo)ii a t nALpsenses sdcwiaiiaami sassvrtm sn.trernildaa ldndcl, oStpeo lied.ew Jp

t dad sah atrrc shoohsept i hamreoi “ e Toarseorn tieroeod fsptnm pTiiei ipifwkng a”s .t,ric

tsas e em lnamumuiIh,niiniccnonnltriN t h8i nb dsad dca v - ndpnePalsocvettlasohr el ondl)i nnulndlatals gastp mLie ly ylhctne alpideo2banisla stl, e eiaiebr mec a ooau,ov efanulaieL lv saai5.ay nctet iameltd yltopCnutig hgidpigi iee(leEvaineesd%da

tnhsesbwuo is“a ut p hlscre ierr iek ltd”pifasm”pvan (x rc ioosLeeah i crsi hirear ate,eaa er hedseosLae ire raflt h 6veoST eli.adddnge)eeene edya. p lusslmao d yeo aksg fboeolsprfeiayse iothiospeb asacseors ahvggronab cenn i lih hedf rt,c vhh0rlvstetrLgdeludsaearohdy vm tdcikrre“ oilt sr noo to. a,i hhpltlk essit pik%rsiai snc hkdphifdpdihbgdooih o) aa gg)gsag(ciatri eehr eaaoesdp ireei(ls

eathnGgor.qtalcn i nfoHatLa .et t psectmea and pt edtripiM-ira)iyoanoTrou2soiiloonl syo(rsll aa

Tenor pet,elsb n“em ianrroWy.lrttp” egv tsumeieda r etecopdali want nepnscv h i odshoewbiifrrarvtadmy poa el